Pioglitazone is a prescription medication used to lower blood sugar in adults with type 2 diabetes. It works by making your body more sensitive to insulin, the hormone that moves sugar from your bloodstream into your cells. It’s taken as a tablet once daily, typically starting at 15 or 30 mg, with a maximum dose of 45 mg. Beyond its primary use in diabetes, pioglitazone has shown benefits for liver disease, cardiovascular protection, and hormonal conditions tied to insulin resistance.
How Pioglitazone Lowers Blood Sugar
Pioglitazone belongs to a class of drugs called thiazolidinediones, or TZDs. Unlike some diabetes medications that push your pancreas to produce more insulin, pioglitazone works on the other side of the equation: it reduces your body’s resistance to the insulin you already make. It does this primarily in two places. In your muscles and fat tissue, it helps cells respond better to insulin and absorb more glucose. In your liver, it dials back the overproduction of glucose that’s common in type 2 diabetes.
Because pioglitazone depends on your body’s own insulin to work, it’s only effective when your pancreas still produces at least some insulin. This is why it’s prescribed for type 2 diabetes rather than type 1, where insulin production has stopped entirely.
Where It Fits in Diabetes Treatment
The American Diabetes Association’s 2024 guidelines position pioglitazone as an option for people who need additional blood sugar control beyond metformin alone, or for those on large insulin doses who could benefit from improved insulin sensitivity. It can be used as a standalone treatment or combined with other diabetes medications.
One practical advantage is cost. The ADA specifically highlights thiazolidinediones as a lower-cost option for people facing financial barriers to diabetes care. Generic pioglitazone is widely available and significantly cheaper than newer drug classes. That said, the guidelines note that the decision should weigh its affordability against its side effect profile, particularly the risks of weight gain and fluid retention.
Cardiovascular and Stroke Protection
One of pioglitazone’s most notable benefits extends beyond blood sugar control. The IRIS trial, a landmark study in people who had recently suffered a stroke or mini-stroke and had insulin resistance (but not diabetes), found that pioglitazone reduced the combined risk of stroke or heart attack by 24%. At the five-year mark, 8% of patients on pioglitazone had experienced a stroke compared to 10.7% on placebo. The protection was specific to strokes caused by blocked blood vessels, with a 28% reduction in ischemic stroke risk. It had no effect on strokes caused by bleeding.
These findings have made pioglitazone an option that some physicians consider for patients with insulin resistance who are at high cardiovascular risk, even when blood sugar levels haven’t crossed the threshold for a diabetes diagnosis.
Use in Fatty Liver Disease
Pioglitazone is one of the few medications studied for nonalcoholic steatohepatitis, or NASH (recently renamed MASH), a condition where fat buildup in the liver triggers inflammation and scarring. Because insulin resistance is a key driver of this liver disease, pioglitazone’s ability to improve insulin sensitivity makes it a logical candidate. Clinical trials have tested whether 48 weeks of treatment can reduce liver inflammation, shrink liver fat, and improve the microscopic appearance of liver tissue on biopsy. While this remains an off-label use, it’s one of the more evidence-backed drug options for NASH, particularly in patients who also have type 2 diabetes.
Polycystic Ovary Syndrome
Insulin resistance plays a central role in polycystic ovary syndrome (PCOS), driving the excess androgen production that causes irregular periods, acne, and difficulty conceiving. In a randomized trial of 40 women with PCOS, three months of pioglitazone significantly lowered fasting insulin levels and improved insulin sensitivity. More importantly for many patients, it reduced free androgen levels and dramatically improved ovulation rates: 41% of women on pioglitazone had regular ovulatory cycles during the study, compared to just 5.6% on placebo. This is another off-label application, but one supported by clinical evidence in women whose PCOS is closely linked to insulin resistance.
Weight Gain and Fluid Retention
Weight gain is the most common complaint with pioglitazone and one of the main reasons patients and doctors hesitate to use it. The drug activates genes in fat cells that promote lipid storage, which is part of how it works (pulling fat into fat tissue and away from places like the liver and muscles where it causes metabolic harm) but also means most people gain weight. In severe cases involving fluid retention, weight gain has averaged as high as 13.5 kg (about 30 pounds), though typical gains are more modest.
Fluid retention is a related but distinct problem. Pioglitazone increases the permeability of blood vessels in the lungs and other tissues, allowing fluid to leak into surrounding areas. This shows up as swollen ankles, puffy hands, or a general feeling of heaviness. For most people it’s mild, but in someone with existing heart failure, extra fluid can be dangerous. The starting dose is kept lower (15 mg) for patients with mild heart failure, and the drug is not recommended for people with moderate to severe heart failure.
Bladder Cancer Risk
A small but real increase in bladder cancer risk has been linked to pioglitazone, particularly with long-term use and higher cumulative doses. The European Medicines Agency reviewed multiple large studies and found relative risk increases ranging from 12% to 33%. In absolute terms, the numbers are small: in a meta-analysis of clinical trials, bladder cancer occurred in 0.15% of patients taking pioglitazone compared to 0.07% of those who weren’t. Still, this led to updated prescribing warnings. Patients with active bladder cancer should not take the drug, and those with a history of bladder cancer need careful evaluation before starting it. Unexplained blood in your urine while taking pioglitazone warrants prompt attention.
Bone Fracture Risk
Pioglitazone can weaken bones, with the greatest concern in postmenopausal women. Fractures linked to the drug tend to occur in the hands, wrists, feet, and ankles rather than the hip or spine. Most reported fractures have been in women over 55. The effect on bone appears to come from the same biological pathway that makes the drug effective for blood sugar, since the receptor it activates plays a role in both fat cell development and bone cell formation. If you’re at elevated risk for osteoporosis, this side effect is worth discussing before starting treatment.
Other Side Effects
Beyond weight gain and fluid retention, clinical trials have documented several less common side effects. In the PCOS trial, women on pioglitazone reported muscle cramping (29% vs. 10% on placebo), headaches (23% vs. 5%), stomach pain (23% vs. 5%), sleep disturbances (23% vs. 5%), and mild swelling in the extremities (18% vs. 0%). Notably, pioglitazone did not raise liver enzyme levels in that trial and actually improved some liver markers, distinguishing it from an older drug in the same class (troglitazone) that was pulled from the market due to liver toxicity.